Table 3 Breast Cancer Related Cumulative Charges by Receptor Status and Charge Type
From: Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer
Health care charges ($US) | HER2 + ER+/PR+/HER2 + or ER-/PR-/HER2 + n = 142 | HER2- TNBC or ER+/PR+/HER2- n = 521 | HER2 + vs. HER2- | ||
|---|---|---|---|---|---|
Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | p-value | |
Facilities/ Technical | 36,523 (28,082) | 34,647 (39,683) | 28,707 (26,418) | 24,207 (32,460) | 0.00 |
Physician/ Professional | 18,191 (14,195) | 16,138 (17,411) | 15,648 (12,973) | 12,577 (17,458) | 0.04 |
Pharmacy | 101,145 (94,243) | 10,1374 (147,132) | 25,529 (39,646) | 7,303 (42,884) | < 0.0001 |
Total Anticancer Treatment | 82,890 (81,269) | 81,783 (127,300) | 7,929 (21,782) | 1,364 (6,006) | < 0.0001 |
Clinical Trial | 96 (430) | 0 (0) | 39 (199) | 0 (0) | 0.26 |
Chemotherapy | 10,443 (15,582) | 4,417 (14,415) | 6,222 (13,642) | 1,074 (5,461) | < 0.0001 |
Hormonal Therapy | 496 (3,889) | 0 (0) | 935 (5,660) | 0 (0) | 0.46 |
Biologic Therapy | 71,855 (72,075) | 6,5471 (117,006) | 732 (12,692) | 0 (0) | < 0.0001 |
Other Medication(s) | 18,255 (21,988) | 6,517 (29,473) | 17,600 (25,321) | 2,953 (29,228) | 0.02 |